Anke Biotech announced that the company plans to use its own funds to transfer 27.4647% of the shares of Anhui Anke Yu Liangqing Pharmaceutical Co., Ltd., held by three partnership companies including Yan Xinwen and Anqing Qinghong, and Bao Science. The total consideration for the transaction is 54.323,800 yuan. Since the counterparty, Bao Xuejie, is the company's vice president, this transaction is a related transaction. After the transaction is completed, the company will hold 100% of Anke Yu Liangqing's shares, and Anke Yu Liangqing will become a wholly-owned subsidiary of the company. This transaction does not constitute a major asset restructuring, and there is no need to submit it to the shareholders' meeting for review.

Anke Biotech announced that the company plans to use its own funds to transfer 27.4647% of the shares of Anhui Anke Yu Liangqing Pharmaceutical Co., Ltd., held by three partnership companies including Yan Xinwen and Anqing Qinghong, and Bao Science. The total consideration for the transaction is 54.323,800 yuan. Since the counterparty, Bao Xuejie, is the company's vice president, this transaction is a related transaction. After the transaction is completed, the company will hold 100% of Anke Yu Liangqing's shares, and Anke Yu Liangqing will become a wholly-owned subsidiary of the company. This transaction does not constitute a major asset restructuring, and there is no need to submit it to the shareholders' meeting for review.